Anthropic has acquired Coefficient Bio, a stealth biotech startup focused on AI-driven biological research, in an all-stock deal valued at just over $400 million. The acquisition marks Anthropic's most significant move into life sciences to date.

From Stealth to Acquisition in Eight Months

Coefficient Bio was formally founded only eight months ago and had remained almost entirely under the radar. The startup was backed by Dimension, a venture capital firm that owned roughly half the company and is now claiming a staggering 38,513% internal rate of return on the investment.

The Coefficient team was pursuing what it described as "artificial superintelligence for science." Co-founder Samuel Stanton wrote in January that the company was "ushering biopharma into the Intelligence Age," promising to change "everything about how the industry learns and makes decisions."

Joining Anthropic's Life Sciences Push

The Coefficient Bio team will join Anthropic's Health Care Life Sciences division led by Eric Kauderer-Abrams. The acquisition signals Anthropic's ambition to extend Claude's capabilities beyond general-purpose AI and into specialized scientific domains, particularly drug discovery and biological modeling.

Anthropic's previous acquisitions include Bun, the JavaScript runtime, and Vercept. Both Anthropic and Dimension declined to comment on the deal.

AI Labs Race Into Biology

The deal comes as AI companies increasingly look to biology as a frontier application. The ability to model molecular interactions, predict drug candidates, and accelerate clinical research timelines represents one of the most commercially valuable applications of large-scale AI systems. With this acquisition, Anthropic is positioning itself alongside competitors who have made similar bets on computational biology.